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Aims: Evidence-based guidelines for heart failuremanagement dependmainly on current
left ventricular ejection fraction (LVEF). However, fewer studies have examined the impact
of prior LVEF. Patients may enter the heart failure with midrange ejection fraction (HFmrEF)
category when heart failure with preserved ejection fraction (HFpEF) deteriorates or heart
failure with reduced ejection fraction (HFrEF) improves. In this study, we examined the
association between change in LVEF and adverse outcomes.
Methods: HFmrEF patients with at least two or more echocardiograms 3 months apart
at the First Affiliated Hospital of Dalian Medical University between September 1, 2015
and November 30, 2019 were identified. According to the prior LVEF, the subjects were
divided into improved group (prior LVEF < 40%), stable group (prior LVEF between 40
and 50%), and deteriorated group (prior LVEF ≥ 50%). The primary outcomes were
cardiovascular death, all-cause mortality, hospitalization for worsening heart failure, and
composite event of all-cause mortality or all-cause hospitalization.
Results: A total of 1,168 HFmrEF patients (67.04% male, mean age 63.60 ± 12.18
years) were included. The percentages of improved, stable, and deteriorated group
were 310 (26.54%), 334 (28.60%), and 524 (44.86%), respectively. After a period of
follow-up, 208 patients (17.81%) died and 500 patients met the composite endpoint.
The rates of all-cause mortality were 35 (11.29%), 55 (16.47%), and 118 (22.52%), and
the composite outcome was 102 (32.90%), 145 (43.41%), and 253 (48.28%) for the
improved, stable, and deteriorated groups, respectively. Cox regression analysis showed
that the deterioration group had higher risk of cardiovascular death (HR: 1.707, 95% CI:
1.064–2.739, P = 0.027), all-cause death (HR 1.948, 95% CI 1.335–2.840, P = 0.001),
and composite outcome (HR 1.379, 95% CI 1.096–1.736, P = 0.006) compared to
the improvement group. The association still remained significant after fully adjusted for
both all-cause mortality (HR = 1.899, 95% CI 1.247–2.893, P = 0.003) and composite
outcome (HR: 1.324, 95% CI: 1.020–1.718, P = 0.035).
Conclusion: HFmrEF patients are heterogeneous with three different subsets identified,
each with different outcomes. Strategies for managing HFmrEF should include previously
measured LVEF to allow stratification based on direction changes in LVEF to better
optimize treatment.
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INTRODUCTION
Heart failure (HF) represents the final common pathway of
different cardiac diseases and is a major cause of death among
the elderly in many countries (1–4). Currently, risk management
and treatment of HF mainly depend on current left ventricular
ejection fraction (LVEF) in clinical practice (5, 6). In the latest
European Society of Cardiology (ESC) guideline, HF was divided
into HF with reduced ejection fraction (HFrEF), HF with
mid-range ejection fraction (HFmrEF), and HF with preserved
ejection fraction (HFpEF) based on LVEF (7). HFmrEF patients
are encountered with an increasing frequency in contemporary
HF clinics (8). The latest data show that the prevalence of
HFmrEF in hospitalized patients ranged from 13 to 26% (9–11),
while the prevalence in outpatients varied from 9 to 21% (12–
17). Nevertheless, previous studies mostly focused on HFrEF and
HFpEF, with less attention paid to HFmrEF until now (18, 19).
Consequently, less is known regarding the clinical characteristics
of patients with HFmrEF, and with limited evidence on which to
base recommendation for therapy (20).
Indeed, LVEF can be dynamic as the condition of the patient
changes. To date, many investigators have been devoting to
working on LVEF transition, exploring the incidence, predictors,
and associations with outcomes of changes in LVEF in HF
patients (21, 22). Some investigators have suggested that HFmrEF
patients do not represent a distinct group, but rather represent
a heterogeneous group of HFrEF and HFpEF patients, in
whom a change in LVEF resulted in their being categorized
as a unique subset of HF patients. In their view, HFmrEF
represents a transitional state, and can easily progress to HFpEF
or HFrEF. However, it must be pointed that transition into the
HFmrEF category may also occur by either deterioration or
improvement of LVEF. Up to now, there are few studies available
describing their characteristics and clinical outcomes. In this




This retrospective cohort study was approved by the institutional
review board of the First Affiliated Hospital of the Dalian
Medical University. The inclusion criteria were patients admitted
for acute decompensated HF at the First Affiliated Hospital
of Dalian Medical University between September 1, 2015 and
November 31, 2019. The exclusion criterion was a lack of
prior echocardiography for comparison. Details of clinical
characteristics, comorbidities, drug therapies, laboratory values,
and echocardiography findings of the subjects were collected
and recorded from Yidu Cloud. All procedures were conducted
in accordance with the Declaration of Helsinki. As this was a
retrospective research, no informed consents can be obtained.
Classification of HF Cases
We classified current HFmrEF patients as having (1) improved
group (defined as any previously documented LVEF < 40%),
(2) stable group (defined as all previously documented LVEF
between 40 and 50%), and (3) deteriorated group (defined as at
least one previously documented LVEF ≥ 50%). The study flow
chart was shown in Figure 1.
Clinical Definitions
HF is defined as a clinical syndrome with symptoms and/or signs
caused by a structural and/or functional cardiac abnormality
and corroborated by elevated natriuretic peptide levels and/or
objective evidence of pulmonary or systemic congestion (23).
According to echocardiographic data, patients with an EF from
40 to 50% were categorized as HFmrEF.
Adverse Outcomes
Cardiovascular death, all-cause death, and hospitalization for
worsening HF were determined using the Yidu Cloud with
complete follow-up through November 30, 2020. The composite
endpoint was defined as all-cause hospitalization or all-cause
mortality. If these data were unavailable, the status was
ascertained by a telephone calling to the patients.
Statistical Analysis
Statistical analysis was performed using SPSS Statistical
Software, Version 22.0 (SPSS Inc., Chicago, IL, USA). Patients’
characteristics were summarized with continuous variables
expressed as means ± standard deviation and categorical
variables presented as frequencies and percentages. Measurement
data with a non-normal distribution were expressed as the
median (interquartile range). The Kruskal-Wallis test was used
for multi-group comparisons, and single-factor ANOVA was
used for inter-group comparison. Characteristics were compared
across HFmrEF groups using analysis of variance or chi-square
tests, as appropriate. Kaplan-Meier analysis was used to describe
the cumulative incidence of adverse events, and the long-rank
test was used to compare differences.
Univariate and multivariate Cox proportional hazards
regression models were used to investigate the risk factors of
the endpoints. Covariates selected for multivariate Cox analysis
come from either the one with a significance of P < 0.05 in
the univariate analysis or the one that had been proven to
greatly affect the prognosis of HF (Supplementary Tables 1, 2),
including age, male, coronary artery disease, hypertension,
diabetes mellitus, cerebrovascular disease, ICD, beta-blockers,
ACEI/ARB/ARNI, spironolactone, loop diuretics, aspirin, statins,
nitrates, hemoglobin, BNP, creatinine, plasma sodium, d-dimer,
and time interval. The hazard ratios (HR) and 95% confidence
intervals (CI) compare clinical outcomes of cardiovascular death,
all-cause death, hospitalization for worsening HF, and composite
event of all-cause hospitalization or all-cause mortality for stable
group compared with improved group (unadjusted and fully
adjusted) and deteriorated group compared with improved
group (unadjusted and fully adjusted). All P-values represent
the significance of the HRs for stable group compared with
improved group or deteriorated group compared with improved
group. All values were two-tailed, and P < 0.05 was considered
statistically significant.
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FIGURE 1 | Flow diagram of patient flow.
RESULTS
Demographic and Clinical Characteristics
Of 2,929 patients who had physician-diagnosed HFmrEF at our
institution during September 1, 2015 and November 30, 2019,
1,761 patients were excluded due to the lack of availability of an
echocardiogram separated by >3 months apart for comparison.
A total of 1,168 patients were included (67.04% male, mean age
63.60 ± 12.18 years). The percentages of improved, stable, and
deteriorated group were 310 (26.54%), 334 (28.60%), and 524
(44.86%), respectively. The flow chart indicating the inclusion
and exclusion criteria was shown in Figure 1.
The baseline characteristics were shown in Table 1. In
brief, patients in improved group were younger, had a
higher proportion of males, and had a lower frequency of
coronary artery disease, cancer, and hypertension compared
with those in stable and deteriorated groups. There was no
statistical difference in the proportion of NYHA class III–IV
between the three groups at the prior echocardiogram. By
contrast, improved group showed relative lower prevalence of
NYHA class III–IV at the time of inclusion compared to the
remaining two groups. Regarding medical therapies, patients in
improved group were more likely to take angiotensin converting
enzyme inhibitors (ACEI)/angiotensin receptor blockers
(ARB)/angiotensin receptor neprilysin inhibitor (ARNI), beta-
blockers, spironolactone, loop diuretics, and CRT compared to
patients in the remaining two groups. As for laboratory data, the
level of white blood cell, hemoglobin, platelet count, uric acid,
and BNP in the improved group were significantly higher than
other two groups. The average time interval between the two
echocardiogram was 16 months. The interval in the deteriorated
group was longer than that of the remaining two groups. Prior
echocardiography findings showed that patients in improved
group had higher left ventricular diameter and left atrial
diameter, whereas with lowest value of interventricular septal
thickness. Echocardiography findings at the time of inclusion
indicated LVEF in all three subgroups fluctuated between 40 and
50, and the value of LVEF in deteriorated group was higher than
that of improved group. Moreover, improved group still had the
highest left ventricular diameter among the three subgroups;
nevertheless, there was no statistical significance across the three
groups for the remainder of the parameters.
Clinical Outcomes
Over a median follow-up of 40.00 [25.00–53.00] months, there
were 208 patients (17.81%) deaths, and the percentages of
improved, stable, and deteriorated group were 35 (11.29%),
55 (16.47%), and 118 (22.52%), respectively. Five hundred
patients met the composite endpoint (42.81%), and the number
were 102 (32.90%), 145 (43.41%), and 253 (48.28%) for the
improved, stable, and deteriorated groups, respectively. Kaplan-
Meier analysis showed that the mortality and composite outcome
in improved group was significantly lower than that in stable
and deteriorated groups (Figures 2, 3). However, there was
no statistical difference in the rates of cardiovascular death
and hospitalization for worsening HF among the three subsets
(Supplementary Figures 1, 2).
Cox regression analysis indicated that the deteriorated group
showed a significantly higher risk of composite endpoint
compared with patients in improved group (HR 1.379, 95%
CI 1.096–1.736, P = 0.006). This difference was mainly due to
trends toward increased risk of all-cause mortality (HR 1.948,
95% CI 1.335–2.840, P = 0.001). The association remained
significant after adjustment for potential confounders for both
mortality (HR = 1.899, 95% CI 1.247–2.893, P = 0.003) and
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TABLE 1 | Baseline demographics and clinical characteristics of the enrolled heart failure patients stratified by the directional change in LVEF.





group (n = 524)
P-value
Age (years) 63.60 ± 12.18 60.08 ± 13.089† 62.92 ± 12.10*† 66.11 ± 11.09*9 <0.0001
Male (n, %) 783 (67.04%) 226 (72.90%)† 237 (70.96%)† 320 (61.07%)*9 0.0004
Systolic blood pressure (mmHg) 136.2 ± 23.33 133.0 ± 22.22† 136.3 ± 23.25 138.0 ± 23.86* 0.0118
Diastolic blood pressure (mmHg) 80.46 ± 13.77 81.85 ± 14.11† 80.77 ± 13.23 79.43 ± 13.84* 0.0437
Heart rates 82.21 ± 22.02 85.76 ± 21.03† 82.60 ± 22.87 79.85 ± 21.79* 0.0009
Body weight (kg) 73.77 ± 13.26 75.84 ± 15.13† 74.38 ± 13.10 72.22 ± 11.97* 0.0037
Body mass index (kg/m2 ) 26.15 ± 4.034 26.66 ± 4.1 25.29 ± 3.70 26.27 ± 4.15 0.5814
Prior NYHA class III–IV (n, %) 322 (27.56%) 84 (27.10%) 95 (28.44%) 143 (27.29%) 0.9126
NYHA class III–IV at the time of
inclusion (n, %)
406 (34.76%) 89 (28.70%)9† 130 (38.92%)* 187 (35.68%)* 0.0204
Comorbidities
Coronary artery disease (n, %) 633 (54.20%) 148 (47.74%)9† 187 (55.99%)* 298 (56.87%)* 0.0258
Atrial fibrillation (n, %) 310 (26.54%) 67 (21.61%) 93 (27.84%) 150 (28.63%) 0.0699
Cancer (n, %) 52 (5.65%) 10 (3.26%)† 15 (4.49%) 41 (7.82%)* 0.0116
Cerebrovascular disease (n, %) 179 (15.33%) 36 (11.61%) 55 (16.47%) 88 (16.79%) 0.1055
Diabetes mellitus (n, %) 414 (35.45%) 97 (31.29%) 125 (37.43%) 192 (36.54%) 0.1980
Hypertension (n, %) 719 (61.56%) 166 (53.55%)9† 211 (63.17%)* 342 (65.27%)* 0.0027
Therapy
ACEI/ARB/ARNI (n, %) 652 (55.82%) 187 (60.32%)† 197 (58.98%)† 268 (51.15%)*9 0.0139
Aspirin (n, %) 683 (58.48%) 176 (56.77%) 209 (62.57%) 298 (56.87%) 0.1982
Beta-blockers (n, %) 885 (75.77%) 266 (85.81%)9† 267 (79.94%)*† 352 (67.18%)*9 <0.0001
Digoxin (n, %) 154 (13.18%) 62 (20.00%)† 36 (10.78%)* 56 (10.69%)* 0.0002
Loop diuretics (n, %) 432 (36.99%) 145 (46.77%)9† 121 (36.23%)* 166 (31.69%)* <0.0001
Nitrates (n, %) 438 (37.50%) 103 (33.23%)9 144 (43.11%)* 191 (36.45%) 0.0280
Spironolactone (n, %) 596 (51.03%) 227 (73.23%)9† 173 (51.80%)*† 196 (37.40%)*9 <0.0001
Statins (n, %) 763 (65.33%) 197 (63.55%) 235 (70.36%) 331 (63.17%) 0.0726
Warfarin (n, %) 226 (19.35%) 55 (17.74%)† 52 (15.57%)† 119 (22.71%)*9 0.0252
Pacemaker (n, %) 81 (6.93%) 14 (4.52%) 22 (6.59%) 45 (8.59%) 0.0784
ICD (n, %) 18 (1.54%) 8 (2.58%) 5 (1.50%) 5 (0.95%) 0.1825
CRT (n, %) 22 (1.88%) 14 (4.52%)9† 5 (1.50%)* 3 (0.57%)* 0.0002
Laboratory values
White blood cell (10∧9/L) 7.655 ± 3.135 8.061 ± 3.386† 7.595 ± 3.007 7.452 ± 3.042* 0.0231
Hemoglobin (g/L) 136.9 ± 21.64 141.1 ± 21.859† 136.9 ± 20.66* 134.4 ± 21.77* <0.0001
Platelet (10∧9/L) 208.7 ± 66.64 222.4 ± 80.989† 202.0 ± 59.32* 205.0 ± 60.34* 0.0001
Creatinine (µmol/L) 76.00 (62.00, 97.00) 79 (64.25, 99.00) 76.00 (63.00, 98.00) 74.00 (61.00,
95.00)
0.6160
UA (µmol/L) 409.4 ± 138.0 440.9 ± 161.19† 412.5 ± 131.9* 390.3 ± 124.5* <0.0001
Na+ (mmol/L) 141.7 ± 3.130 141.6 ± 3.169 141.6 ± 3.021 141.7 ± 3.179 0.7728
Glu (mmol/L) 6.351 ± 2.614 6.370 ± 2.853 6.373 ± 2.489 6.326 ± 2.560 0.9619
D-dimer (µg/L) 420 (210.0, 970.0) 410 (210.0, 970.0) 410 (190.0 880.0) 455.0 (230.0,
1,025)
0.2193








Left ventricular ejection fraction (%) 46.26 ± 10.57 32.41 ± 5.6269† 43.61 ± 2.711*† 56.16 ± 3.088*9 <0.0001
(Continued)
Frontiers in Cardiovascular Medicine | www.frontiersin.org 4 August 2021 | Volume 8 | Article 697221
Zhang et al. HFmrEF: Prior LVEF and Prognosis
TABLE 1 | Continued





group (n = 524)
P-value
Left ventricular diameter (mm) 53.52 ± 7.875 59.69 ± 7.2139† 54.22 ± 6.706*† 49.61 ± 6.466*9 <0.0001
Left atrial diameter (mm) 42.44 ± 7.225 44.02 ± 6.3139† 42.64 ± 6.711*† 41.44 ± 7.838*9 <0.0001
Interventricular septal thickness (mm) 10.68 ± 1.914 10.38 ± 1.6619† 10.80 ± 1.951* 10.78 ± 2.007* 0.0103
E/e′ 13.02 ± 5.621 13.46 ± 5.383 13.47 ± 6.075 12.38 ± 5.372 0.0534
Echocardiography findings at the time of inclusion
Left ventricular ejection fraction (%) 43.75 ± 2.875 43.35 ± 2.874† 43.70 ± 2.757 44.02 ± 2.925* 0.0047
Left ventricular diameter (mm) 53.92 ± 6.604 56.24 ± 6.2599† 54.78 ± 6.759*† 51.84 ± 6.076*9 <0.0001
Left atrial diameter (mm) 42.85 ± 6.782 42.28 ± 6.630 43.52 ± 6.433 42.77 ± 7.079 0.0682
Interventricular septal thickness (mm) 10.76 ± 1.998 10.55 ± 1.871 10.73 ± 2.153 10.90 ± 1.960 0.0568
E/e′ 13.07 ± 5.628 12.19 ± 5.645 13.18 ± 5.344 13.49 ± 5.770 0.0668
NYHA, New York Heart Association; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; ICD, implantable
cardioverter defibrillator; CRT, cardiac resynchronization therapy; BNP, B-type natriuretic peptide; Glu, glucose; UA, uric acid; E/e
′
, mitral Doppler early velocity/mitral annular early velocity.
* is compared with Improved group P < 0.05, 9 is compared with Stable group P < 0.05,
†
is compared with Deteriorated group P < 0.05.
FIGURE 2 | Kaplan-Meier curves for mortality for the subsets of heart failure with midrange ejection fraction.
composite outcome (HR: 1.324, 95% CI: 1.020–1.718, P= 0.035).
Moreover, compared to improved group, deteriorated group
also experienced a 1.71-fold increase in risk of cardiovascular
death (HR: 1.707, 95% CI: 1.064–2.739, P = 0.027), albeit not
reaching statistical significance in fully adjusted analysis. As with
outcomes for hospitalization for worsening HF, HRs between the
three subgroups did not show statistical differences. In addition,
no significant differences in outcomes between patients in the
improved and stable groups were seen for any of the endpoints
in either unadjusted or fully adjusted analysis. The results were
shown in Figure 4.
DISCUSSION
This study demonstrated that HFmrEF patients were a
heterogeneous group of patients comprised of at least three
different subsets. Additionally, the characteristics and clinical
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FIGURE 3 | Kaplan-Meier curves for composite outcome of mortality or hospitalization for the subsets of heart failure with midrange ejection fraction.
outcomes of HFmrEF patients among subgroups defined by the
prior directional changes in LVEF are significantly different.
Risk stratification in HF is an important clinical problem
(24, 25). Previous studies have elucidated that the demographics
of patients with HFmrEF lied in between those of HFpEF and
HFrEF patients, but in general were more similar to HFpEF
patients, with a heavier burden of hypertension and atrial
fibrillation/flutter (10, 12, 13, 26). Nevertheless, HFmrEF also
resembled HFrEF showing a higher burden of ischemic heart
disease (9, 27–29). In our study, we found that the HFmrEF
cohort suffered from a heavy burden of comorbidities, such as
hypertension (61.56%), coronary heart disease (54.20%), and
atrial fibrillation/flutter (26.54%). Our research also indicated
that the characteristics of patients withinHFmrEF subgroup were
significantly different from the HFrEF and HFpEF subgroups.
For example, patients in the deteriorated group were older, more
female, andmore likely to have hypertension, which were features
consistent with HFpEF. By contrast, the deteriorated cohort
had higher prevalence of coronary artery disease, which was in
keeping with a HFrEF phenotype.
Regarding treatment, previous literatures suggested that
HFmrEF patients received a mixture of medications indicated
for both HFrEF and HFpEF patients (30, 31). Indeed, our
study found that HFmrEF patients were prescribed medications
recommended for HFrEF (digoxin, ACEI or ARB) as well as
for HFpEF (calcium channel blockers). In our cohort, more
than 50% patients received the traditional first-line agents of
beta-blockers, ACEI/ARB, and aldosterone antagonist.Moreover,
we found that patients in the improved group were more
likely to take beta-blockers, ACEI/ARB/ARNI, spironolactone,
and CRT than patients in the remaining two groups. The
reason may be that neurohormonal blocking agents were only
recommended for the patients with HFrEF but not HFpEF
in HF management guidelines. Overall, these discrepancies
underscored the considerable heterogeneity between patients in
the HFmrEF population.
Notably, prior studies illustrated that the prognosis of
HFmrEF patients was distinct from those of HFrEF and HFpEF.
A 5-year follow-up ofmortality showed that all-causemortality in
HFmrEF was higher than the rate of HFpEF patients, but lower
than that of HFrEF patients (32, 33). However, HFmrEFmortality
at 1 year after discharge was similar to that of HFpEF (10,
34, 35). The findings from four community-based longitudinal
cohorts showed that age was an important clinical predictor
of new onset HFmrEF (27). Meanwhile, a latest separate study
demonstrated age ≥80 years was associated with a higher risk
of mortality within 1 year following discharge in the HFmrEF
group compared with other HF types (35). In this study, our
results also identified age as an independent risk factor for
both mortality and composite outcome. Moreover, we found
the adverse events of patients with HFmrEF varied considerably
between subgroups and the clinical course was closely associated
with the directional changes in LVEF that brought them into the
mid-range. Unsurprisingly, patients in deteriorated group had a
worse prognosis compared to other HFmrEF phenotypes, with a
remarkably increased risk of a median follow-up of 40.00 months
mortality and hospitalization, indicating the urgent need for
careful follow-up of this group. The unfavorable outcomes may
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FIGURE 4 | Forest plot of clinical outcomes in HFmrEF subgroups.
be related to a large reduction of LVEF and a substantial increase
in LV diameter in deteriorated group. The adverse alternations in
cardiac structure and function are most likely due to the lower
usage of guideline-directed medical therapy and the relatively
high prevalence of coronary artery disease, as coronary artery
disease was always associated with higher risk of mortality and
worsening LVEF. In the large Improve Heart Failure Therapies in
the Outpatient Setting registry, patients without prior myocardial
infarction and non-ischemic HF etiology were both associated
with a >10% improvement in LVEF (36).
These findings suggested that for HFmrEF patients, previous
changes in the direction of LVEF may provide important
prognostic value, and clinicians should consider previous
changes in LVEF when devising treatment plans.
Limitations
Nevertheless, we must note that this study still has several
limitations. Firstly, considering the single-center nature of our
study, the findings may not be generalizable to other settings.
Secondly, the interval between the prior echocardiogram and
the inclusion to the study was not exactly the same. Patients
with echocardiography assessments within a short time period
might have been less likely to exhibit a change in EF category.
Although multivariate Cox regression models were applied to
adjust for the interval between echocardiography assessments,
residual confounding might have been a limitation. Thirdly, we
can only obtain the medical record of patients hospitalized at
our center, and we have no way of confirming when HF was first
diagnosed, as this might have taken place at other hospitals. Thus,
in this study, not every patient’s echocardiogram time relative
to initial HF diagnosis can be clearly recorded. Lastly, clinical
outcomes were ascertained mainly depending on a telephone
calling to the patients. Therefore, only a small number of patients
in this cohort underwent the last follow-up echocardiography.
In the near future, a large prospective cohort or a randomized-
controlled study is necessary to understand the characteristics
and evaluate the effects of drugs in HFmrEF population.
Conclusions
In conclusion, differences in the prevalence of risk factors and
underlying etiology may generate different effects on LVEF
transition, and thus different outcomes. The condition of HFpEF
to HFmrEF is a dangerous and complex pathological process,
which always implied worse clinical outcomes. These findings
would remind clinicians to pay more attention to previous
echocardiography results in HFmrEF patients, and to consider
the impact of direction changes in LVEF on the prognosis of
patients when planning management strategies.
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